The Company was incorporated as a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 10, 2023, issued by the Registrar of Companies, Central Registration Centre.
Major Events and Milestones: 2023 Incorporation of the Company 2024 Demerger, transfer and vesting of the Demerged Undertaking from Sanofi India Limited into the Company on a going concern basis pursuant to the Scheme
2020
-Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030.
2021
-Sanofi completed acquisition of Kadmon.
-Sanofi completed acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics.
-Sanofi launched its new global employee share ownership plan.
-Sanofi established three-year collaboration with Stanford Medicine to accelerate immunology research.
2022
-Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology.
-Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine.
-Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth.
-Sanofi recognized by S&P as one of the most sustainability- committed companies.
-Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board.
2023
-Sanofi's Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability.
-Sanofi completes acquisition of Qunol.
-Sanofi completes acquisition of Provention Bio, Inc.
- Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care.
2024
-Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline.
|